Magnesium for anxiety and what the clinical trials actually found
Magnesium alone has not established relief from anxiety. In the evidence assessed by Boyle and colleagues (2017) and Rawji and colleagues (2024), positive questionnaire findings were concentrated in particular stress and menstrual-symptom settings, and results varied between investigations. Several designs introduced an additional uncertainty: magnesium was paired with other ingredients, or there was no inactive comparison (Pouteau et al., 2018; Oddoux et al., 2022).
The participants were not all being treated for a diagnosed psychiatric condition. The reviews encompass people recruited because of premenstrual complaints, perceived stress and several different clinical circumstances (Boyle et al., 2017; Rawji et al., 2024). In Oddoux et al.'s 2022 observational investigation, everybody received a compound preparation, leaving the natural course of symptoms and the individual ingredients' effects indistinguishable.
What magnesium for anxiety research is testing
Magnesium has a recognised place in ordinary physiology, including enzyme activity and the functioning of nerves and muscles (National Institutes of Health, 2026). That role supplies a reason for investigation, rather than an answer about anxiety treatment. Reviewing the intervention literature in 2017, Boyle and colleagues judged the supporting clinical work to be of poor quality.
A blood test examines a narrow part of the body's magnesium supply. Most of the mineral is held in bone or within cells, and the NIH's 2026 reference explains why a serum result cannot faithfully represent those stores.
Magnesium intake, status and supplementation
Investigations differ in what they observe: food intake, concentration in the bloodstream, or the response after a trial treatment. A dietary estimate cannot stand in for a treatment outcome. Nor can a serum value establish what individual tissues contain, as the NIH explained in 2026.
In Botturi et al.'s 2020 synthesis, the separate investigations of panic disorder and generalised anxiety disorder failed to find a statistically significant association with serum magnesium. The authors also examined research on other psychiatric diagnoses, including depressive and neurodevelopmental conditions. That breadth makes the review unsuitable as evidence for a blood-based marker unique to anxiety.
Anxiety symptoms versus anxiety disorders
A clinical anxiety diagnosis was not always required. The 2017 synthesis by Boyle, Lawton and Dye brought together samples selected for mild anxious symptoms, premenstrual syndrome, postpartum status or hypertension, meaning that the groups did not share a single diagnostic criterion. The later collection by Rawji et al. (2024) also included groups with diagnosed generalised anxiety disorder or adjustment disorder accompanied by anxiety.
Assessments were not uniform either. The methods catalogued by Rawji et al. (2024) included the Hamilton Anxiety Scale alongside participant-reported symptom ratings. A score from one of these measures cannot establish equivalence between separate diagnostic groups. The study of competitive anxiety and self-talk illustrates an altogether different setting, involving sport rather than supplementation.
Anxiety and sleep outcomes have also been examined separately in magnesium research. A related article on magnesium for sleep explains why changes in sleep questionnaires or objective measurements cannot automatically be interpreted as evidence of reduced anxiety.
How magnesium might affect anxiety and stress signalling
An electrical message passes along a nerve through the movement of charged particles across its cell boundary. The National Institutes of Health reference published in 2026 describes magnesium as contributing to the passage of calcium and potassium across cell membranes, a process involved in nerve conduction, muscular contraction and maintenance of a normal heartbeat. This physiological function does not demonstrate relief of anxious feelings, and a blood test does not establish the mineral concentration within the tissues producing those signals.
Direct human tests remain scarce. Campedelli and colleagues (2026) found relatively little clinical evidence connecting those mechanisms with changes recorded on mood or anxiety measures. Their review rated certainty for anxiety outcomes as low to moderate.
Neuronal signalling and excitability
A proposed route involves a particular receptor for glutamate. In their 2017 synthesis, Boyle and colleagues described how magnesium inhibits the NMDA receptor, a molecular action associated with reduced neuronal hyperexcitability. This does not establish an improvement in patients' reported symptoms, and Campedelli et al. (2026) found direct human testing of the proposed mechanism to be scarce.
Other proposed explanations extend beyond a single receptor. Botturi and colleagues (2020) considered glutamatergic transmission, regulation of the stress-response axis and inflammation while examining psychiatric conditions more broadly. This wider scope cannot identify a pathway specific to anxiety, while the 2026 synthesis by Campedelli et al. reported limited human mechanistic evidence.
Stress response and magnesium status
Stress can change a blood measurement. Pouteau and colleagues (2018) described a hormonal response in which magnesium leaves cells, more of it is excreted in urine and the serum concentration subsequently decreases. Their participants were selected for substantial stress and suboptimal circulating magnesium. The selection criteria cannot determine whether changes recorded later came from the mineral, the added vitamin or another influence.
Serum values tell only part of the story. The NIH (2026) describes magnesium's role in moving calcium and potassium ions through cell membranes during nerve signalling, while also explaining that most stores lie inside cells or in bone. A blood measurement cannot identify the mineral concentration within nerve tissue.
Which magnesium forms have been studied for anxiety
Magnesium did not enter these experiments as one standardised substance. The review by Rawji and colleagues (2024) identifies oxide, sulphate and lactate dihydrate, used with differing groups and research schedules. A symptom rating obtained with one compound in one setting cannot establish the response to a different salt.
Citrate and glycinate also feature in the later review by Campedelli and colleagues (2026). The authors did not derive a single new pooled estimate because the underlying studies differed too much for that calculation.
Oxide, citrate, lactate and other preparations
The women investigated by De Souza et al. (2000) had mild symptoms associated with menstruation, rather than being recruited on the basis of a formal anxiety-disorder diagnosis. In their double-blind crossover experiment, forty-four participants were studied across conditions involving magnesium oxide alone, B6 alone, the two nutrients together and an inactive preparation, allowing comparisons unavailable in single-arm research. An inactive preparation was therefore available as a comparator.
Pouteau's 2018 randomised study varied the addition of vitamin B6, not whether participants received magnesium at all. One group took magnesium lactate and the other took magnesium alongside B6. Consequently, differences between their scores speak to the extra ingredient; the trial did not provide a placebo estimate for magnesium supplementation itself.
There was no separate comparison group in the 2022 investigation by Oddoux and colleagues. Patients with adjustment disorder accompanied by anxiety received a preparation containing two magnesium compounds as well as B6 and a fish-protein derivative. Any change during observation could have involved the natural course of symptoms or more than one constituent, so the mineral's individual contribution cannot be identified.
Limits of comparing formulations
A preferred magnesium salt cannot be identified from these comparisons. In its assessment of the earlier trials, Rawji and colleagues (2024) found oxide frequently represented but could not choose an optimal preparation. Campedelli and colleagues (2026) examined additional formulations, but because the participant groups, intervention protocols and outcomes varied substantially across the underlying studies, the authors did not calculate a new pooled estimate of treatment effects.
One favourable finding in the 2000 De Souza experiment concerned a narrowly defined menstrual-symptom outcome. The overall test found no significant difference among interventions, whereas a comparison specified in advance favoured the joint magnesium and B6 preparation for complaints that included irritability and anxiety. Because the intervention involved both ingredients, this particular finding cannot establish the result of magnesium administered alone.
Which people were studied for magnesium and anxiety
A diagnosed anxiety disorder did not unite the groups studied in the early interventions. Boyle and colleagues (2017) identified 18 interventions involving differently selected groups: some recruited people with mild anxiety, others enrolled people for menstrual symptoms, for the period following childbirth or because they had hypertension. Those eligibility differences limit how far an apparent effect in any one group can be applied to others.
The later synthesis by Rawji et al. (2024) covered an even broader range of clinical circumstances. Its participants included children receiving migraine care, people having open-heart surgery, adults reporting marked stress and patients with clinical diagnoses involving anxiety. Their reasons for entering a study were therefore not interchangeable.
Participants under stress or with premenstrual symptoms
Entry to Pouteau et al.'s 2018 study depended on two measures: the DASS-42 stress subscale and a serum value classified as suboptimal for magnesium. The adults recruited were aged 18 to 50. Randomisation then compared a magnesium preparation with that preparation supplemented by B6; neither group received placebo.
De Souza and colleagues studied menstrual complaints. The measured symptoms encompassed nervous tension, changing mood, anxiety and irritability. In their 2000 crossover experiment, the same women received separate magnesium and B6 interventions, the combined formulation and a placebo at different stages of the comparison. No overall treatment difference emerged, although a prespecified contrast favoured both nutrients together.
Without magnesium, placebo participants also improved in Ebrahimi et al.'s 2012 trial of 126 women with premenstrual syndrome. However, mean syndrome scores differed significantly between magnesium and placebo after treatment (p < 0.05). The composite outcome included several premenstrual symptoms rather than isolating an anxiety-specific effect.
Baseline magnesium and anxiety measurements
For enrolment in Pouteau et al.'s (2018) experiment, participants had to meet both a stress-score requirement and a criterion based on magnesium measured in serum. The NIH reference issued in 2026 explains a limitation of that measurement: the mineral is largely located in bone and cells, beyond what a circulating sample can describe accurately. Selecting participants by serum concentration therefore does not establish their total tissue magnesium status.
Blood associations and intervention outcomes are separate kinds of evidence. Botturi et al.'s 2020 review described two studies in which serum magnesium had no statistically significant association with panic or generalised anxiety disorder. Rawji and colleagues (2024) instead reviewed interventions spanning multiple diagnoses and symptom-defined populations. Neither type of study supplies the missing result for magnesium alone against placebo across those groups.
What magnesium clinical trials found about anxiety symptoms
The direction of the findings depended partly on who was studied. Boyle and colleagues (2017) reported favourable ratings in some groups with mild anxiety or premenstrual symptoms, but the studies involving postpartum anxiety did not show that pattern. In 2024, Rawji and colleagues counted favourable self-reported anxiety outcomes in five of seven studies measuring them; they also highlighted small samples and disparate methods.
Placebo-controlled anxiety trials
Placebo formed part of the 2000 design. In a trial involving forty-four women, De Souza and colleagues compared magnesium oxide, B6, their combination and an inactive preparation across crossover periods. Although the overall treatment comparison was not significant, a prespecified contrast for the combined preparation reached p = 0.040 for a defined cluster of premenstrual anxiety-related complaints.
Ebrahimi et al. (2012) assigned 126 women with premenstrual syndrome to magnesium, B6 or placebo. Syndrome scores declined in all three arms, including placebo, yet magnesium differed significantly from placebo after treatment (p < 0.05). The measure combined several symptoms rather than isolating anxiety.
The results were not uniformly favourable. In Boyle et al.'s 2017 synthesis, trials involving people recruited after childbirth did not detect a reduction in anxiety symptoms following magnesium, even though favourable findings were reported for some other groups. The reviewers described the intervention evidence as poor and called for stronger randomised studies. Favourable comparisons alone would leave out those essential qualifications.
Magnesium with other active ingredients
Pouteau et al. (2018) compared magnesium with and without B6, but had no placebo arm. In 264 adults, DASS-42 stress scores fell by 44.9% with B6 and 42.4% without it at Week 8, with no significant overall difference. Among 162 participants with severe or extremely severe stress, the respective reductions were 50.1% and 41.3% (adjusted between-group difference 3.16 points; p = 0.0203). This planned subgroup comparison evaluates added B6, not magnesium against placebo.
Noah and colleagues (2021) returned to the participants from Pouteau's earlier randomised experiment instead of studying a newly recruited cohort. In their later analysis, mean anxiety ratings fell in both groups, but the arms did not differ significantly at Week 4 or Week 8. The authors acknowledged that the analysis was post-hoc and relied on self-reported measures.
Oddoux et al. (2022) had no control arm. Of 93 analysed patients with adjustment disorder and anxiety, 39, reported as 41.9%, reached a reduction of ≥50% on the Hamilton scale. Everybody took a preparation combining magnesium, B6 and fish-derived material, and spontaneous symptom improvement could not be excluded as an explanation.
Clinical trial findings at a glance
Study | Design and participants | Measurement | Interpretive boundary |
De Souza et al., 2000 | Forty-four women with premenstrual symptoms; crossover comparison including placebo | No overall treatment difference; a defined contrast favoured the magnesium and B6 combination, p = 0.040 | Specific symptoms and combined ingredients |
Ebrahimi et al., 2012 | 126 women with premenstrual syndrome; magnesium, B6 or placebo | All groups improved; magnesium differed from placebo (p < 0.05) | Composite PMS measure, not an anxiety-specific effect |
Pouteau et al., 2018 | 264 stressed adults; magnesium with or without B6 | 44.9% vs 42.4% overall (not significant); 50.1% vs 41.3% in severe stress (p = 0.0203) | No placebo; both groups received magnesium |
Noah et al., 2021 | Post-hoc anxiety analysis of Pouteau's participants | Both arms improved; no statistically significant difference between them | Same randomised sample, different outcome |
Oddoux et al., 2022 | Adjustment disorder with anxiety; multi-ingredient product | 41.9% of 93 analysed met the specified response threshold | No control group |
Rawji et al., 2024 | Systematic review of studies measuring anxiety | Five of seven studies reported lower self-reported anxiety | Small and heterogeneous evidence base |
Separate papers did not always represent separate trials. Noah et al. (2021) reported anxiety outcomes from people already randomised in Pouteau's earlier stress study. Oddoux et al.'s 2022 percentage came instead from an uncontrolled group taking a multi-ingredient preparation. Neither analysis included an inactive comparison of magnesium alone: Pouteau's groups both received it, while Oddoux used no comparator.
What magnesium supplement safety studies and guidelines show
Safety has separate endpoints. According to the National Institutes of Health (2026), excess magnesium from ordinary food is unlikely in healthy people, whereas larger amounts supplied as supplements or medicines can cause gastrointestinal adverse effects. A change in anxiety scores cannot erase a known exposure-related risk.
Gastrointestinal effects and kidney function
Exposure changes the risk. High supplemental magnesium intake can cause diarrhoea, nausea and abdominal cramps, with severe toxicity associated with abnormal cardiac rhythm and respiratory problems (National Institutes of Health, 2026). The intervention studies considered by Rawji et al. (2024) generally recorded milder and less frequent reactions.
Pouteau et al. (2018) recorded potential adverse reactions. Treatment-related events were suspected for 12.1% receiving magnesium plus B6 and 17.4% receiving magnesium without B6. Those percentages lack a placebo reference. Impaired renal clearance is separately identified as a magnesium toxicity risk by the National Institutes of Health (2026).
Rawji et al. (2024) reported predominantly mild reactions, with loose stools mentioned most often. A broader account from the National Institutes of Health (2026) documents gastrointestinal effects from high supplemental or medicinal exposure.
Interactions and short trial follow-up
Some effects of magnesium involve other medicines rather than anxiety itself. National Institutes of Health guidance (2026) identifies oral bisphosphonates and certain antibiotics among drugs whose interaction with magnesium matters; diuretic and proton-pump-inhibitor use may also influence magnesium balance.
Oddoux et al. (2022) described predominantly non-serious digestive reactions in people taking the combined preparation. Along with magnesium, that product included B6 and a fish protein hydrolysate. With every participant receiving the same mixture, the study could neither apportion unwanted reactions to one ingredient nor establish which component accounted for symptom changes.
The length of observation places another limit on safety reporting. In Rawji et al.'s 2024 review, treatment lasted between five days and six months, with four to eight weeks the usual interval. Findings made within those windows cannot document consequences beyond them. Separate discussions of evidence standards for mixed remedies appear in research on herbal medicine monographs.
What is proven about magnesium for anxiety and what is not
Biochemistry and clinical outcomes answer different questions. Magnesium's involvement with NMDA receptors was discussed by Boyle et al. (2017), while the National Institutes of Health (2026) describes its contribution to membrane ion movement. The same Boyle review called anxiety intervention evidence poor. Rawji et al. (2024) subsequently noted favourable scores, but these came from a small, varied body of studies.
A favourable questionnaire change identifies an outcome in its study population. It does not by itself establish that magnesium, taken without other active ingredients, improves anxiety relative to placebo.
Pouteau et al. (2018) had no placebo group. Its overall stress comparison was not significant, but the severe-stress subgroup favoured magnesium plus B6. Noah et al. (2021) found no significant anxiety difference between arms in a post-hoc analysis of the same participants. Neither test establishes magnesium's effect against placebo.
Without a control group, the Oddoux study cannot separate intervention effects from changes over time. Oddoux et al. (2022) recorded a Hamilton-scale response among patients with adjustment disorder who received a mixture containing magnesium. The investigators themselves acknowledged the possibility of spontaneous symptom change. The contribution, if any, of magnesium alone remains undetermined.
Blood concentration does not solve the causality problem either. In two studies reviewed by Botturi et al. (2020), serum magnesium showed no statistically significant relationship with panic or generalised anxiety disorders. The National Institutes of Health (2026) also points out how poorly serum levels represent mineral content in tissues. Neither finding tests anxiety outcomes after isolated supplementation.
The later systematic assessments leave meaningful uncertainty. Campedelli et al. (2026) judged the anxiety evidence to have low to moderate certainty, with few human tests of the biological mechanisms; variation among trials ruled out a new meta-analysis. Rawji et al. (2024) could not identify the best magnesium preparation. Noah et al. (2021) acknowledged the limits of their post-hoc analysis, while Boyle et al. (2017) had called for better-controlled trials.
Frequently asked questions
How long has magnesium been tested for anxiety in clinical trials?
Trial duration has varied too widely to define a standard response window. Rawji et al. (2024) found exposures lasting from five days through six months, with most interventions running for four to eight weeks. These schedules describe how the research was conducted. They do not show when, or whether, anxiety symptoms would improve in an individual.
Can a magnesium deficiency contribute to anxiety symptoms?
Magnesium contributes to nerve impulse conduction through its involvement in membrane ion transport (National Institutes of Health, 2026). This physiology does not demonstrate that deficiency produces an anxiety disorder. Botturi et al. (2020) reported no statistically significant serum association in two relevant studies, and NIH guidance explains why circulating magnesium incompletely represents tissue stores.
Is magnesium glycinate proven better for anxiety than magnesium citrate?
Neither salt has demonstrated superiority. Both forms appeared among the interventions surveyed by Campedelli et al. (2026), but study methods and participants differed substantially. Oxide was more prominent in earlier research, and Rawji et al. (2024) explicitly found no basis for selecting an optimal magnesium form.
Does magnesium affect anxiety and sleep in the same way?
Improvement in a sleep rating cannot be assumed to represent improvement in anxiety. The studies collated by Rawji et al. (2024) examined both types of questionnaire, and some reported a favourable change in at least one outcome. Sleep quality and anxious symptoms remain separate measurements, with results limited to the populations and assessment tools used.
Were people with diagnosed anxiety disorders included in magnesium trials?
Yes. Diagnosed participants were included. The groups considered by Rawji et al. (2024) included generalised anxiety and adjustment disorder alongside stress-related and other populations. Oddoux et al. (2022) studied adjustment disorder using a combined supplement, but without a comparator arm capable of isolating a magnesium effect.
Sources
- Boyle NB, Lawton C, Dye L. The Effects of Magnesium Supplementation on Subjective Anxiety and Stress: A Systematic Review. Nutrients. 2017;9(5):429. DOI 10.3390/nu9050429.
- Rawji A, Peltier MR, Mourtzanakis K, et al. Examining the Effects of Supplemental Magnesium on Self-Reported Anxiety and Sleep Quality: A Systematic Review. Cureus. 2024;16(4):e59317. DOI 10.7759/cureus.59317.
- Botturi A, Ciappolino V, Delvecchio G, et al. The Role and the Effect of Magnesium in Mental Disorders: A Systematic Review. Nutrients. 2020;12(6):1661. DOI 10.3390/nu12061661.
- Pouteau E, Kabir-Ahmadi M, Noah L, et al. Superiority of magnesium and vitamin B6 over magnesium alone on severe stress in healthy adults with low magnesemia: A randomized, single-blind clinical trial. PLOS ONE. 2018;13(12):e0208454. DOI 10.1371/journal.pone.0208454.
- Noah L, Dye L, Bois De Fer B, Mazur A, Pickering G, Pouteau E. Effect of magnesium and vitamin B6 supplementation on mental health and quality of life in stressed healthy adults: Post-hoc analysis of a randomised controlled trial. Stress and Health. 2021;37(5):1000–1009. DOI 10.1002/smi.3051.
- De Souza MC, Walker AF, Robinson PA, Bolland K. A synergistic effect of a daily supplement for 1 month of 200 mg magnesium plus 50 mg vitamin B6 for the relief of anxiety-related premenstrual symptoms: a randomized, double-blind, crossover study. Journal of Women’s Health & Gender-Based Medicine. 2000;9(2):131–139. DOI 10.1089/152460900318623.
- Ebrahimi E, Khayati Motlagh S, Nemati S, Tavakoli Z. Effects of magnesium and vitamin B6 on the severity of premenstrual syndrome symptoms. Journal of Caring Sciences. 2012;1(4):183–189. DOI 10.5681/jcs.2012.026.
- Oddoux S, Violette P, Cornet J, et al. Effect of a Dietary Supplement Combining Bioactive Peptides and Magnesium on Adjustment Disorder with Anxiety: A Clinical Trial in General Practice. Nutrients. 2022;14(12):2425. DOI 10.3390/nu14122425.
- Campedelli L, Cicoli A, Lastretti M, et al. Magnesium supplementation for anxiety and depression: a systematic review of clinical evidence and mechanistic insights. Food Production, Processing and Nutrition. 2026;8:73. DOI 10.1186/s43014-026-00424-6.
- National Institutes of Health, Office of Dietary Supplements. Magnesium: Fact Sheet for Health Professionals. 6 January 2026. https://ods.od.nih.gov/factsheets/Magnesium-HealthProfessional/
This article is for general information and is not medical advice. It was reviewed for accuracy by a qualified clinician; decisions about your health should be made with your own doctor.
Related
How self-talk patterns relate to competitive anxiety in sport
Herbal Medicine Monographs: What Commission E Still Teaches
Magnesium for sleep and what the research really shows
What research shows about whether creatine is bad for your kidneys
What antioxidants are and why more is not always better
Why vitamin A deficiency remains a leading cause of child blindness
Whether creatine causes hair loss and what the DHT study found